Avalo Therapeutics Inc. (AVTX) Stock Performance – 23 October 2026
Trading Activity
- Price change (24‑hour period ending 01:58 PM CET, Friday 23 Oct 2026): –39.23 %.
- Current trading price: USD 7.45.
- Shares outstanding: 53.6 million.
- Market capitalisation: USD 657.5 million.
- Volume traded in last 24 hours: USD 195.1 million.
- Month‑end change: –51.31 %.
Technical Indicators
- 200‑day simple moving average: USD 16.33.
- 52‑week high: USD 24.27 (recorded 05 Jul 2026).
- 52‑week low: USD 6.85 (recorded 22 Oct 2026).
Performance of Related Stocks – 24‑Hour Period
| Company | Ticker | % Change | Current Price (USD) | Market Cap (USD mn) | P/E Ratio | Notes |
|---|---|---|---|---|---|---|
| Prospect Capital | PBB | –1.32 % | 1.49 | 784.7 | 24.2 | – |
| Varex Imaging | VREX | –0.05 % | 18.41 | 782.2 | 35.25 | Filed merger report with Teledyne Technologies; shareholder complaints received; merger under antitrust and UK NISA review. |
| Alerus | ALRS | +2.68 % | 32.18 | 780.5 | 29.28 | Form 4 filing: director Randy Newman transferred stock to spouse; no operational update. |
| Koppers | KOP | –1.43 % | 40.75 | 781.8 | – | – |
| Apnimed | APMD | +2.11 % | 18.53 | 786.8 | 2 | – |
Company Overview – Avalo Therapeutics Inc.
- Sector: Health Care – Pharmaceuticals
- Business Focus: Precision medicine for immunology, immuno‑oncology, and rare genetic diseases.
- Operational Stage: Clinical‑stage.
- Public Listing: Nasdaq, debut 15 Oct 2015.
Avalo Therapeutics continues to advance its pipeline of targeted therapeutics aimed at patients with unmet medical needs. The recent decline in share price reflects market volatility rather than a change in the company’s strategic direction or financial position.
